Niobay Metals Inc (NYSEAMERICAN:NBY) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Friday.
Niobay Metals (NYSEAMERICAN NBY) opened at C$4.20 on Friday. Niobay Metals has a one year low of C$2.25 and a one year high of C$5.00.
TRADEMARK VIOLATION NOTICE: “ValuEngine Downgrades Niobay Metals Inc (NBY) to Strong Sell” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/11/12/valuengine-downgrades-niobay-metals-inc-nby-to-strong-sell.html.
Niobay Metals Company Profile
NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.
Receive News & Ratings for Niobay Metals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niobay Metals Inc and related companies with MarketBeat.com's FREE daily email newsletter.